MEMBERS ONLY
Continue Reading
This article is available to Vanguard members. Join to access all physician-curated content.
Monograph
Bupropion-naltrexone sustained-release (brand name Contrave) is an FDA-approved combination weight-loss drug, approved in September 2014. It pairs bupropion — a norepinephrine and dopamine reuptake inhibitor used as an antidepressant and…
MEMBERS ONLY
This article is available to Vanguard members. Join to access all physician-curated content.
Bug report, content request, or general comment — we read everything.